Dianthus Therapeutics logo
Dianthus Therapeutics
DNTH | NASDAQ
Chart Builder DCF Calculator
$89.55
-$2.26 (-2.46%)
At close: Nov 16, 2026, 4:00 PM ET
$89.02
-$0.53 (-0.59%)
After-hours: Nov 16, 2026, 7:51 PM ET

Dianthus Therapeutics Company Profile

Company profile explained

Company Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Key Executives

Name Position
Marino Garcia President, Chief Executive Officer & Director
Kristina Maximenko Chief People Officer
Adam Veness Senior Vice President, General Counsel & Secretary
Edward G. Carr Senior VP & Chief Accounting Officer
Jennifer Davis Ruff Vice President and Head of Investor Relations & Corporate Affairs.
Judson Taylor Senior Vice President & Head of Technical Operations
Rashieda Gluck Head of Clinical Development Operations
Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer
Scott Nogi Head of Business Operations
Simrat Randhawa Executive Vice President and Head of R&D

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 18, 2026 4 Filing
Sep 18, 2026 S-3ASR Automatic shelf registration statement of securiti...
Sep 03, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 11, 2026 4 Filing
Aug 11, 2026 4 Filing
View All SEC Filings ➞
Dianthus Therapeutics
Dianthus Therapeutics logo
Country United States
IPO Date Jun 21, 2018
Industry Biotechnology
Sector Healthcare
Employees 92
CEO Marino Garcia

Contact Details

7 Times Square New York, New York 10036 United States

Stock Details

Ticker Symbol DNTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001690585
CUSIP Number 252828108
ISIN Number US2528281080
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.